---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019282"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:41:17.703643+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xenon Q1 net loss $19.7M; XEN1101 Phase 3 on track for H2 2022

## Summary
- Net loss $19.7M vs $15.8M YoY; revenue $8.8M, up from $4.4M on Neurocrine milestone.
- Cash $537.9M, sufficient to fund operations into at least 2024.
- XEN1101 Phase 2b met primary endpoint; FDA End-of-Phase 2 meeting Q2 2022; Phase 3 start H2 2022.
- Phase 2 X-NOVA for MDD initiated; topline results expected in 2023.
- XEN496 Phase 3 EPIK in KCNQ2-DEE ongoing; completion anticipated in 2023.

## SEC filing metadata
- accession: 0001564590-22-019282
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000156459022019282/0001564590-22-019282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000156459022019282/xene-8k_20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019282
- JSON: https://secwatch.observer/filing/0001564590-22-019282.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019282.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.